Sec Form 4 Filing - Baker Brian Lee @ Turning Point Therapeutics, Inc. - 2021-01-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Baker Brian Lee 2. Issuer Name and Ticker or Trading Symbol Turning Point Therapeutics, Inc. [ TPTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP of Finance and Admin. (Last) (First) (Middle) C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, STE. 200 3. Date of Earliest Transaction (MM/DD/YY) 01/07/2021 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 01/07/2021 M( 1 ) 11,905 A $ 2.19 15,713 ( 2 ) D Common Stock 01/07/2021 M( 1 ) 1,299 A $ 3.2 17,012 D Common Stock 01/07/2021 M( 1 ) 4,545 A $ 5.12 21,557 D Common Stock 01/07/2021 M( 1 ) 10,689 A $ 7.43 32,246 D Common Stock 01/07/2021 S( 1 ) 2,800 D $ 122.65 ( 3 ) 29,446 D Common Stock 01/07/2021 S( 1 ) 900 D $ 120.16 ( 4 ) 28,546 D Common Stock 01/07/2021 S( 1 ) 5,200 D $ 121.57 ( 5 ) 23,346 D Common Stock 01/07/2021 S( 1 ) 21,825 D $ 122.44 ( 6 ) 1,521 D Common Stock 01/07/2021 S( 1 ) 513 D $ 123.02 ( 7 ) 1,008 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 2.19 01/07/2021 M( 1 ) 11,905 ( 8 ) 08/08/2027 Common Stock 11,905 $ 0 14,069 D Stock Option (right to buy) $ 3.2 01/07/2021 M( 1 ) 1,299 ( 9 ) 03/08/2028 Common Stock 1,299 $ 0 1,298 D Stock Option (right to buy) $ 5.12 01/07/2021 M( 1 ) 4,545 ( 10 ) 11/05/2028 Common Stock 4,545 $ 0 11,039 D Stock Option (right to buy) $ 7.43 01/07/2021 M( 1 ) 10,689 ( 11 ) 02/19/2029 Common Stock 10,689 $ 0 30,356 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Baker Brian Lee C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO, CA92121 SVP of Finance and Admin. Signatures /s/ Annette North, Attorney-in-Fact 01/08/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. ( 2 )The Reporting Person acquired 365 shares on June 12, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 427 shares on December 10, 2020 pursuant the ESPP. ( 3 )The weighted average sale price for the transaction reported was $122.65, and the range of prices were between $122.50 and $123.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ( 4 )The weighted average sale price for the transaction reported was $120.16, and the range of prices were between $119.90 and $120.68. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ( 5 )The weighted average sale price for the transaction reported was $121.57, and the range of prices were between $120.96 and $121.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ( 6 )The weighted average sale price for the transaction reported was $122.44, and the range of prices were between $121.97 and $122.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ( 7 )The weighted average sale price for the transaction reported was $123.02, and the range of prices were between $122.98 and $123.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ( 8 )One-fourth of the option vested on July 6, 2018. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. ( 9 )Vests in 36 equal successive monthly installments on each monthly anniversary of January 1, 2018. ( 10 )1/48th of the shares vest monthly following November 6, 2018. ( 11 )25% of the shares vest on February 12, 2020 and 1/48th of the shares vest monthly thereafter over the next three years.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.